ViiV Healthcare's long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia (1780.0000p, +21)
Shionogi to buy IntraBio Inc. for $2.0B (¥315.69B) up front (¥2693.5000, -92.5)
Japan approves marketing of Shionogi's VTAMA for atopic dermatitis in pediatric patients (¥2884.0000, -20)
Japan approves addition of booster dose indication to Shionogi & Co.'s manufacturing and marketing authorization for COVGOZE (¥2887.5000, -16.5)
BARDA's Project BioShield exercises $36.9M (~JPY5.88B) procurement option to procure Fetroja (¥2915.0000, +5.5)
Verrica Pharmaceuticals completes enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH for the Treatment of Common Warts, with Topline Data Expected Q1 2027 ($4.91, 0.00)
FDA approves Tivicay PD to treat HIV in newborns
StreetAccount Asia Macro Headlines
Transcript Intelligence: Shionogi & Co. Q1 Earnings Guidance
Transcript Intelligence: Shionogi & Co. Q1 Earnings Themes
Powered by FactSet Research Systems Inc.